Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival and resistance.The company's offerings include developing a pipeline of novel, orally bioavailable, small molecule therapies to target critical intervention points in pathways of resistance to overcome treatment failure in cancer, enabling healthcare providers to discover potential treatments that offer hope to people with cancer.

Patents 15show all

  • 10
    C07D - Heterocyclic compounds
  • 4
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 3
    A61K - Preparations for medical, dental, or toilet purposes
  • 3
    C07H - Sugars

Clinical Trials 2show all

2Phase 1

Contact Information

200 Powder Mill Road
Wilmington, DE DE 19803
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$72,000,00011-502019-06-12Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2019-06-12$60,000,000Series BOrbiMed
2017-10-20$12,000,000Series Unknown